# Dongkoo Bio&Pharma

> Dongkoo Bio&Pharma is a VC fund backing Biotechnology, Pharmaceutical and Biopharma. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Nov 2021
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://www.dongkoo.com/eng

Dongkoo Bio&Pharma is an bio&Pharma Company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Seed | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| South Korea | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Valted Seq | Valted Seq is a discovery stage biopharmaceutical company that utilizes big data to develop lifesaving therapeutics.focused on the discovery of neurodegenerative pathways and biomarkers to inform and accelerate the development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advancedtherapeutics. To achieve this, the company has created the world’s largest repository of single-cell sequencing data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimer’s and Parkinson’s.It was established in Gaithersburg, Maryland by | $10M | Seed | Nov 02, 2021 |  |
| Neuraly | Neuraly, a startup biotech company, was formed in 2016 following foundational research by world class neuroscientists led by Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins School of Medicine. Following the acquisition of exclusivelicenses to patents covering the composition of matter and methods of use, research supporting the development of NLY01 was recently published in Nature Medicine1. These data demonstrated the critical role of the glial compartment of the neural tissue in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. | $36M | Series A | Jul 18, 2018 |  |
| D&D Pharmatech | D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases,providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients. | $36M | Series A | Jan 01, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Geon Investment](https://shizune.co/investors/profile/geon-investment) — VC Fund, 2 deals together
- [LB Investment](https://shizune.co/investors/profile/lb-investment) — VC Fund, 2 deals together
- [Magna Investment](https://shizune.co/investors/profile/magna-investment) — VC Fund, 2 deals together
- [Maryland Venture Fund](https://shizune.co/investors/profile/maryland-venture-fund) — VC Fund, 2 deals together
- [Octave Life Sciences](https://shizune.co/investors/profile/octave-life-sciences) — VC Fund, 2 deals together
- [Smilegate Investment](https://shizune.co/investors/profile/smilegate-investment) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)

## FAQ

### What does Dongkoo Bio&Pharma invest in?

Dongkoo Bio&Pharma invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dongkoo Bio&Pharma last invest?

The most recent investment recorded for Dongkoo Bio&Pharma closed in Nov 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co